全文获取类型
收费全文 | 387篇 |
免费 | 19篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 14篇 |
妇产科学 | 13篇 |
基础医学 | 32篇 |
口腔科学 | 10篇 |
临床医学 | 37篇 |
内科学 | 128篇 |
皮肤病学 | 5篇 |
神经病学 | 7篇 |
特种医学 | 17篇 |
外科学 | 39篇 |
综合类 | 7篇 |
预防医学 | 22篇 |
眼科学 | 8篇 |
药学 | 10篇 |
肿瘤学 | 56篇 |
出版年
2023年 | 7篇 |
2022年 | 22篇 |
2021年 | 21篇 |
2020年 | 9篇 |
2019年 | 19篇 |
2018年 | 16篇 |
2017年 | 12篇 |
2016年 | 7篇 |
2015年 | 11篇 |
2014年 | 12篇 |
2013年 | 23篇 |
2012年 | 19篇 |
2011年 | 24篇 |
2010年 | 14篇 |
2009年 | 13篇 |
2008年 | 22篇 |
2007年 | 13篇 |
2006年 | 14篇 |
2005年 | 17篇 |
2004年 | 17篇 |
2003年 | 13篇 |
2002年 | 15篇 |
2001年 | 5篇 |
2000年 | 8篇 |
1999年 | 4篇 |
1997年 | 4篇 |
1996年 | 6篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 2篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1974年 | 4篇 |
1973年 | 6篇 |
1970年 | 2篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1966年 | 1篇 |
1964年 | 1篇 |
排序方式: 共有406条查询结果,搜索用时 31 毫秒
1.
Hassan Chamsi-Pasha Alaa Abdulmoneim Waqar H Ahmed Khaled F Al-Shaibi Aref Ajam Hassan Bakhamees Abdullah K Ashmeg 《Journal of the American Society of Echocardiography》2004,17(1):70-72
A 24-year-old man presented with a 24-hour history of pain and numbness in his left arm. The patient's clinical presentation of peripheral embolism was corroborated by angiography. Echocardiographic study showed masses in both right and left atria. Pathologic specimen from the embolus confirmed the diagnosis of aspergillosis. 相似文献
2.
Honn KV Aref A Chen YQ Cher ML Crissman JD Forman JD Gao X Grignon D Hussain M Porter AT Pontes JE Powell I Redman B Sakr W Severson R Tang DG Wood DP 《Pathology oncology research : POR》1996,2(1-2):98-109
Rates of prostate cancer (PCa) have increased so dramatically over the last decade that the age adjusted incidence rate for PCa is now greater than that any other cancer among men in the United States. This review, published as a three part series, provides a state-of-art assessment of the PCa problem in its divergent aspects.Part 1 covers epidemiology, incidence and progression. Several epidemiological studies have demostrated that first degree male relatives of men with PCa are at increased risk of developing the disease. Familial and genetic factors as well as medical, anthropometric, dietary, hormonal and occupational factors involved in PCa are discussed. Postmortem examination of the prostate in men without evidence of PCa documented a high frequency of adenocarcinoma. Latent disease occurred as early as the second decade of life. Although there is no significant difference in incidence between Caucasian and African-American males, high grade prostatic intraepithelial neoplasia (HGPIN) is higher in the latter group. While dietary fat, androgens and certain environmental factors may be determinants for PCa, the exact mechanism of tumorigenesis is still relatively unknown. The current thinking of the role of genomic instability, chromosomal alterations, tumor suppressor genes and the androgen receptor are explored. 相似文献
3.
Ziaee Masumeh Atapour Maryam Marouf Aref 《Proceedings of the National Academy of Sciences, India. Section B.》2018,88(1):411-419
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences - Persistence and efficacy of four Iranian diatomaceous earth formulations was assessed against Sitophilus... 相似文献
4.
S. Aref M. El-Sherbiny E. Azmy T. Goda T. Selim M. El-Refaie T. Emaad 《Indian journal of hematology & blood transfusion》2008,24(1):1-6
Introduction
Endostatin is the C-terminal antiangiogenic fragment of the extracellular matrix protein collagen XVIII, and is generated by tumor-derived proteases. The levels and the prognostic relevance of serum endostatin in AML patient is not fully clear.Aim
To evaluate serum levels of endostatin in acute myeloid leukemia patients before chemotherapy and after achieving complete remission and to correlate endostatin levels with patients outcome.Materials and methods
Serum samples from 30 adult patients (22 males and 8 females, median age 37, range 19–66 years) with AML had been taken before chemotherapy was administered. In addition 20 out of 30 patients were reinvestigated again at complete remission (CR). Ten samples from healthy normal persons of matched age and sex were evaluated as a reference control group. Serum endostatin levels were determined using enzyme linked immune sorbent assay (ELISA).Results
Endostatin serum levels were not significantly different in the pretreatment AML patients as compared to that in normal controls (P>0.05). In AML patients the baseline endostatin levels were significantly lower than at CR (P=0.001). No significant correlation were detected between pretreatment serum endostatin levels and age, peripheral blood white cell counts, platelet counts, bone marrow blast cell counts, blast cell distribution ratio. The prognostic value of sE was also evaluated by dividing AML patients into high and low sE groups using the 75 percentile sE levels of the patients group as cutoff. The authors found that patients group in the high sE group survived for significantly longer time than those patients in the low sE group.Conclusions
Elevated endostatin levels at AML diagnosis is a good prognostic marker for patients’ outcome. Wide scale study is recommended in order to establish the clinical value of this study.5.
Aref S El-Sherbiny M Mabed M Menessy A El-Refaei M 《Hematology (Amsterdam, Netherlands)》2003,8(6):385-391
Extracellular proteolytic enzymes of the urokinase-type plasminogen activator (uPA) and metalloproteinase (MMP) family play a crucial role in the matrix degradation and tissue remodeling process characteristic of malignant disorders. The receptor for urokinase plasminogen activator (uPAR) serves to localize and intensify the action of UPA and is expressed on the surface of malignant cells. Although the biological significance of MMP-9 and soluble urokinase receptor in growth and progression of lymphoid neoplasm is understood, its clinical significance in acute myeloid leukemia (AML) has not been fully elucidated. In this study, we determined the levels of soluble urokinase-type plasminogen activator receptor (suPAR), cellular uPAR and sMMP-9 in 43 newly diagnosed AML patients at diagnosis, before chemotherapy, and also studied 10 normal subjects served as a control group. After chemotherapy suPAR and MMP-9 were determined at remission and relapse. The levels of suPAR, cellular PAR were significantly higher (P= 0.001, 0.001) and MMP-9 was significantly lower (P=0.001) in AML patients at diagnosis as compared to controls. suPAR and MMP-9 levels were significantly lower in AML patients who achieved complete remission (CR) as compared to those who did not (P= 0.001 for both). Levels of suPAR and MMP-9 were significantly correlated to peripheral blood blast cells (r= 0.88, P= 0.001; r= 0.65, P= 0.001, respectively) and blast cell distribution ratio (BCDR, r= 0.84, P= 0.001; r=65, P= 0.001, respectively). suPAR, cellular PAR and MMP-9 were significantly higher in patients with extramedullary infiltration as compared with those without (P= 0.001, 0.001, <0.05). The suPAR, cellular uPAR, and MMP-9 levels were uneven in AML FAB subtypes being highest in M5(P<0.05 for all). MMP-9 and suPAR levels were correlated with the disease status. In AML survivors, MMP-9, cellular uPAR and suPAR were significantly lower as compared to non-survivors (P= 0.001 for all). In conclusion, MMP-9 and su PAR levels might be used as a marker for disease activity and may contribute to blast cell dissemination. MMP-9 and suPAR may be target molecules in the strategy of treatment of AML. 相似文献
6.
Summary A 54-year-old female presented with a three-year history of proximal muscle weakness and arthralgia. EMG, muscle enzymes and biopsy and other tests were consistent with idiopathic polymyositis. At a later stage, she developed plaques of morphoea involving the dorsum of hands and forearms. There was no evidence of systemic sclerosis throughout the course of the disease. In our opinion, such association appeared as an unusual overlap syndrome that provided a new constellation of features in connective tissue disease. 相似文献
7.
8.
Todd C. Villines Subhi J. Al’Aref Daniele Andreini Marcus Y. Chen Andrew D. Choi Carlo N. De Cecco Damini Dey James P. Earls Maros Ferencik Heidi Gransar Harvey Hecht Jonathon A. Leipsic Michael T. Lu Mohamed Marwan Pál Maurovich-Horvat Edward Nicol Gianluca Pontone Jonathan Weir-McCall Gudrun M. Feuchtner 《Journal of Cardiovascular Computed Tomography》2021,15(2):180-189
9.
10.
Ramezani A Velayati AA Eslamifar A Banifazl M Ahmadi F Maziar S Razeghi E Kalantar E Amirkhani A Aghakhani A 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2008,12(2):143-146
Although the efficacy of hepatitis B vaccines in patients undergoing chronic hemodialysis (HD) treatment has been documented, the persistence of immunity in this population remains largely unknown. In this study we evaluated the persistence of hepatitis B vaccine immunity in HD patients. We followed 37 hepatitis B vaccinated HD patients (following a four-dose vaccination schedule of 40 mug injections intramuscularly in the deltoid muscle at 0, 1, 2, and 6 months) for up to one year to evaluate the persistence of immunity (as indicated by serum levels of hepatitis B surface antibody (anti-HBs) equal to or higher than 10 IU/L). One year after vaccination, 18.9% of patients had lost their anti-HBs (transient responders), while 81.1% still had detectable antibodies in the serum (persistent responders). From 81.1% of persistent responders 11.5% and 88.5% were weak and high responders, respectively. There was no significant difference between persistent and transient responders regarding age, sex, or nutritional factors. We did not find any factors that related to maintaining protective levels of anti-HBs in HD patients. It seems that an antibody titer above 100 IU/L following vaccination is necessary in order to maintain that level of antibody one year later. 相似文献